Business Wire

Exscientia Initiates Prospective Observational Study in Ovarian Cancer

18.7.2023 14:00:00 EEST | Business Wire | Press release

Share

Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response. This first of its kind observational study in solid tumours will run at multiple medical research centres in Europe with a focus on ovarian cancers. It aims to inform and enable future studies in other solid tumours.

Ovarian cancer represents a high unmet need for predicting patient response to diverse therapy options. The study will be conducted in collaboration with the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, one of the leading non-profit clinical research networks in gynaeco-oncology worldwide.

“We are thrilled to work with Exscientia to advance the state of science and potential treatment of ovarian cancer patients," said Professor Philipp Harter M.D., Ph.D., Head of Gynaecology and Gynaeco-Oncology at Evangelische Kliniken Essen-Mitte, Germany, and Chair of the AGO Study Group. "This study will enable us to explore new ways to identify the right treatment for individual patients, especially in cases with no available molecular biomarkers. We look forward to being a part of this important scientific evaluation.”

By combining high-content imaging of samples and deep learning image analysis, the company’s AI-based precision medicine platform leverages a patient’s biopsies to assess drug activity at a single cell level ex vivo. The EXCYTE-1 trial follows the prospective EXALT-1 trial in haematologic malignancies, the first study to leverage AI-driven ex vivo drug testing to guide treatment selection and improve outcomes in patients with advanced haematological cancers. Patients who received drugs prioritised by the platform experienced significantly better outcomes, with 54% of patients demonstrating clinical benefit of >1.3-fold enhanced progression free survival (PFS) compared to prior therapy. The EXCYTE-1 trial is designed to expand the scope of Exscientia’s precision medicine platform in solid tumours.

“The outcomes from this study could have broad implications for how we evaluate drug candidates and support clinical practice in the future,” said Dr. Nikolaus Krall, EVP of Precision Medicine at Exscientia. “If established, a robust correlation between our platform’s results and clinical outcomes will support the greater use of human tumour samples in the preclinical development of new drug candidates and translational cancer research. This has the potential to overcome the limited clinical relevance of mouse and other animal models that are presently used. In addition, this study may further pave the way for the use of functional drug testing to guide treatment selection to achieve better patient outcomes.”

About EXCYTE-1 Prospective Observational Study

The EXCYTE-1 trial is a multi-centre two-phase study evaluating the correlation between clinical and ex vivo drug response as measured using Exscientia’s AI-based precision medicine platform in ovarian cancer. The study is designed to compare results from the precision medicine platform to clinical outcomes via tissue collection and drug response analysis.

The objective of the pilot phase of the study is to collect patient tissue samples and analyse the drug response of the tissue in a lab setting before scaling up to a larger expansion phase. Two patient populations will be included: patients newly diagnosed with advanced ovarian cancer and those with relapsed ovarian cancer. Before undergoing therapy, malignant ascites will be collected, accompanied by solid tissues where available. The EVDR of commonly used standard of care therapies will then be evaluated in these patient samples by Exscientia’s AI-based precision medicine platform. These results will be compared against patients’ clinical response to treatment, which will be chosen and evaluated by physicians blinded to the EVDR data. Progression free survival (PFS) of patients will be monitored as the key clinical endpoint and assessed to monitor association with EVDR. Secondary endpoints will include EVDR predicted early relapse and PFS >12 months.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Exscientia Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the collaboration with the AGO Study Group; and the timing and progress of, and data collected during and reported from, the EXCYTE-1 clinical trial, as well as expectations with respect to the outcome or benefit of such trial. Any statement describing Exscientia’s goals, plans, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Sara Sherman
investors@exscientia.ai

Media:
Oliver Stohlmann
media@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release

TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 17:40:00 EET | Press release

Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that coordinated, network-level defenses are reducing the impact of these threats. “AI is changing the economics of fraud

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 17:00:00 EET | Press release

Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro brings decades of experience in the supercomputing industry. During his 16-year tenure as President and CEO of Cray, he led the company through

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 16:30:00 EET | Press release

SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial networks. As demand grows for ubiquitous and resilient connectivity, Direct-to-Device services are expected to become an important c

From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 16:26:00 EET | Press release

Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores that don’t offer Klarna. “Back in 2015, we thought about the future of finance and imagined a day when

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye